Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation

Area of Science:

• Oncology
• Immunotherapy
• Cell Biology

Background:

• Refractory Diffuse Large B-cell Lymphoma (DLBCL) poses significant treatment challenges due to resistance.
• Engineered T-cells, particularly Chimeric Antigen Receptor (CAR) T-cells, offer potential for overcoming drug resistance.

Purpose of the Study:

• To investigate the efficacy of WEE1-engineered T-cells against refractory DLBCL in vitro.
• To assess the ability of these engineered T-cells to target and eliminate DLBCL cells resistant to standard therapies.

Main Methods:

• Development of 5th-generation CAR T-cells targeting the WEE1 antigen on DLBCL cells.
• In vitro evaluation of engineered T-cell cytotoxicity against Rituximab-resistant DLBCL cell lines.
• Analysis of apoptosis, cell cycle, and gene expression (WEE1, BCL2, CDK2) via flow cytometry and RT-PCR.

Main Results:

• Significant increase in DLBCL cell lysis, apoptosis, and necrosis mediated by WEE1-engineered T-cells.
• Demonstrated reduction in the G2M phase of the cell cycle in target cells.
• Observed decrease in WEE1, BCL2, and CDK2 gene expression, indicating potent anti-tumor activity.

Conclusions:

• WEE1-engineered CAR T-cell therapy exhibits strong anti-tumor activity against refractory DLBCL in vitro.
• This approach shows potential for overcoming resistance mechanisms in aggressive lymphoma subtypes.
• Findings support the clinical applicability of WEE1-targeted CAR T-cell therapy for refractory DLBCL.